All In Biotech

Drug Trial Radar · NCT07252440

A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

A Prospective, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Dec 19, 2025

Primary completion

Oct 23, 2028

Study completion Nov 23, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled parallel Phase II core period study to evaluate the efficacy and safety of TTYP01 Tablets in early symptomatic AD (Mild cognitive impairment \[MCI\] due to AD, or mild AD dementia). A total of 180 participants will be randomized into 3 parallel groups: 2 TTYP01 dose groups and 1 placebo group.

Conditions

  • AD
  • Early Alzheimer's Disease

Interventions

  • TTYP01 tables 60mgDrug

    2 TTYP01 30 mg tablets + 1 placebo tablet BID

  • TTYP01 tables 90mgDrug

    (3 TTYP01 30 mg tablets

  • TTYP01 tables 0mgDrug

    3 placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) score at Week 78.Time frame: Baseline to Week 78
  2. Number of participants with Adverse events, serious adverse events, adverse events of special interestTime frame: Baseline to Week 78

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Daping Hospital.

    Chongqing, Chongqing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.